唑来膦酸致弥漫性皮肤不良反应一例报告
本文报告一例53岁原发性骨质疏松女性在静脉给予唑来膦酸2天后出现躯干和手臂融合性红斑性斑疹、左大腿及小腿扩展性紫癜性斑疹的弥漫性皮肤不良反应,无过敏背景或其他合并用药。唑来膦酸常见不良反应为急性期反应和胃肠道反应,皮肤反应少见但可严重。
要点
- 唑来膦酸可致弥漫性皮肤不良反应,多在给药后2天出现。
- 皮肤反应表现多样,多数轻微自限,但也可严重如中毒性表皮坏死松解。
- 用药后需警惕皮肤反应,及时识别并处理。
核心结论
- 唑来膦酸可引起弥漫性皮肤不良反应,包括融合性红斑性斑疹和紫癜性斑疹。
研究设计与样本
- 个案报告:一例53岁原发性骨质疏松女性静脉给予唑来膦酸后出现皮肤不良反应。
主要发现
- 给药2天后躯干和手臂出现融合性红斑性斑疹,左大腿及小腿出现扩展性紫癜性斑疹。
- 患者无过敏背景,未合并其他药物。
关键数值与推荐
- 唑来膦酸常见不良反应为急性期反应(乏力、肌肉骨骼疼痛)和胃肠道反应。
- 罕见皮肤不良反应包括发热性皮疹、斑丘疹、角膜炎、皮炎、B细胞假性淋巴瘤、多形性红斑和血管炎。
- 严重皮肤反应可包括中毒性表皮坏死松解和全血细胞减少。
临床怎么用
- 使用唑来膦酸后应监测皮肤反应,尤其在给药后数天内。
- 出现皮肤反应需评估严重程度,多数自限,但严重者需及时干预。
局限性
- 个案报告,不能确立因果关系或估计发生率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Zoledronic acid, an amino-bisphosphonate, is an antiresorptive drug given intravenously. It is commonly used for the treatment of severe postmenopausal osteoporosis, and it is also used for other types of osteoporosis, management of bone metastasis, multiple myeloma, hypercalcemia, and Paget's disease. The use varies according to these diseases. The drug is usually well-tolerated with the most common side effects being acute-phase reactions with weakness and musculoskeletal pain as well as gastrointestinal effects. However, the increase in usage of zoledronic acid has produced rare reports of side effects, such as atrial fibrillation, atypical fracture, delayed fracture healing, osteonecrosis of the jaw, or buccal or genital mucosa. Less common cutaneous side effects associated with zoledronic acid include fever rash, maculopapular lesions, keratitis, dermatitis, B-cell pseudolymphoma, skin erythema multiform, and vasculitis. Although these cutaneous reactions are generally mild and self-limiting, others can be severe such as toxic epidermal necrolysis and pancytopenia. We hereby describe a case of diffuse skin adverse reactions, a type of confluent erythematous macules in the trunk and arms with extended petechial macules along the left thigh and leg, induced 2 days after the administration of zoledronic acid for primary osteoporosis in a 53-year-old woman, without any allergic context or other associated drugs taken.
引用
- Nassar K, Janani S. Diffuse adverse cutaneous reactions induced by zoledronic acid administration: a case report : Eruptions cutanées diffuses induites par l'administration de l'acide zolédronique. Osteoporos Int. 2021. PMID: 34085118. doi:10.1007/s00198-021-06021-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。